Skip Navigation


Europace Advance Access originally published online on May 2, 2006
Europace 2006 8(6):393-397; doi:10.1093/europace/eul040
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
8/6/393    most recent
eul040v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nisam, S.
Right arrow Articles by Breithardt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nisam, S.
Right arrow Articles by Breithardt, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

ICD

Lessons learned from neutral ICD trials

Seah Nisam1,* and Günter Breithardt2

1 Guidant Corporation, Park Lane, Culliganlaan 2B, 1831 Diegem, Brussels, Belgium ; 2 Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany

Multiple prospective randomized trials with implantable cardioverter defibrillators (ICDs) over the past decade have convincingly established the efficacy of ICD therapy in reducing all-cause mortality, by significantly reducing sudden cardiac death. Nevertheless, four trials have failed to show improved survival. Analysing these, in comparison with the positive trials, provides important information concerning the type of patients not likely to receive benefit from ICDs: (i) those with relatively low mortality (≤18% within 2 years of follow-up; (ii) those whose mechanism of death is predominantly non-arrhythmic; (iii) patients early (within 6 weeks) after infarction.

Key Words: Implantable cardioverter defibrillator, Sudden death, ICD trials

* Corresponding author. fax: +32 2 7141565. E-mail address: snisam{at}guidant.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.